Novartis’ Ilaris fails in late-stage COVID-19 trial
Virtual wards: caring for COVID-19 patients at home could save lives
Merck Snaps Up VelosBio In $2.75B Oncology Deal; Shares Rise
Bristol Myers hints at some problems with an FDA inspection needed for the liso-cel OK, and the Celgene CVR investors are panicking
Biogen Rockets 44% On “Substantial Evidence” For Alzheimer’s Drug Approval
A year after stunning China OK, Shanghai Alzheimer's drugmaker set to enroll first US patient — and the stakes are huge
Promising mRNA tech comes with regulatory, CMC headaches
Pfizer Initiates Phase 2b Study For Cardiovascular Treatment
Novartis’ Aimovig tops topiramate in migraine face-off
3 "Strong Buy" Stocks Poised for a Year-End Rally
John Snow Memo v. Great Barrington – The Johns Hopkins Debate
Regeneron’s COVID-19 antibody cocktail therapy hits safety problem
Oppenheimer’s Leland Gershell on the Future of Biopharma
Covid-19 roundup: Russian biotech seeks permission to produce remdesivir generic; Why did BARDA fund plasma company part-owned by Rick Santorum?
Sanofi Picks Up Kiadis for $359 Million
Regeneron, Lilly Setbacks Raise Questions on the Effectiveness of Antibodies in Severe COVID-19
Sanofi to acquire Kiadis and NK cell tech for $353 million
Humanigen Treats First Patient in Late-Stage COVID-19 Trial
AstraZeneca Sells Rights To Hypertension Drugs For $400M
3 Biotech Stocks in the Hunt for COVID-19 Vaccine; One Analyst Calls Them a 'Buy'
US COVID-19 Cases Top 9 Million, Belgium Announces 6-Week National Lockdown: Live Updates
AstraZeneca sells commercial rights to two drugs in $400 million deal
SARS-CoV-2 might attack red marrow and block new erythrocytes formation
AstraZeneca sells off heart failure and hypertension drugs to Cheplapharm for $400M
NEJM: clinical trial indicates monoclonal antibody lowered hospitalizations and emergency visits
Covid-19 roundup: Flush with $486M contract, AstraZeneca signs Lonza up to manufacture antibodies; BioNTech's Ugur Sahin expects vaccine data 'in a fortnight'
Eli Lilly Nabs $312.5M US Army Contract For Covid-19 Treatment
Two more biotechs price IPOs, bringing total raise to record heights
Novartis Snaps Up Vedero Bio In $280M Deal; Street Says Buy
Eli Lilly Strikes $375M Covid-19 Antibody Supply Deal With US Government